• Boehringer Ingelheim Enhances Central Nervous System Disease Pipeline

• Vanderbilt Center for Neuroscience Drug Discovery Advances Preclinical Schizophrenia Targets

NASHVILLE, Tenn. & INGELHEIM, Germany-Thursday 3 January 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Boehringer Ingelheim and Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) today announced two new global agreements to investigate, develop and commercialize novel small molecules targeting two distinct G-protein coupled receptors (GPCRs) known to engage in the modulation of certain brain circuitries, which are altered in neuropsychiatric conditions such as schizophrenia.

“By joining forces with Vanderbilt University, one of the world’s leading groups integrating basic neuroscience and new translational approaches in neuropsychiatric conditions, Boehringer Ingelheim will strengthen and expand efforts to bring new treatments to patients,” said Bern ... Read more »

PTC Builds on Long History of Philanthropy with Foundation Establishment

NEEDHAM, Mass.-Thursday 3 January 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- PTC (NASDAQ: PTC) today announced the launch of the PTC Foundation to formalize and expand on its three decades of corporate philanthropy – with a focus on STEM and education, community, and employee giving. Rooted in its mission to help “Create a Better Reality,” the PTC Foundation allows community leaders to embrace technology through grant and in-kind software requests, while also empowering employees to positively impact their communities by providing PTC technology and financial grants to the organizations that matter to them.

“The establishment of this foundation is an extension of PTC’s commitment to social responsibility and embodies the values and passion of our employees,” said Aaron von Staats, general counsel of PTC and board member of the PTC Foundation. “Throug ... Read more »